Notice Number: NOT-TR-20-006
Release Date: February 27, 2020
First Available Due Date: April 01, 2020
Expiration Date: April 04, 2022
RFA-TR-18-020 Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
National Center for Advancing Translational Sciences ( NCATS)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Neurological Disorders and Stroke (NINDS)
The National Center for Advancing Translational Sciences (NCATS) informs Program Directors/Principal Investigators (PDs/PIs) holding active Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54) awards of the opportunity to submit administrative supplement requests through the NIH Parent Funding Opportunity Announcement (FOA), PA-18-591, “Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)”.
These supplements may provide short-term and/or catalytic support for projects with a significant and unmet needs. Applicants for the administrative supplements are encouraged to form new collaborations to enhance the reach and impact of the activity. Administrative supplements must add value to the science proposed in the aims of the original project; as such, they must be within the scientific scope of the parent grant. Enthusiasm will be higher for requests that describe a clear outcome and that have the potential for greatest impact across the RDCRN and these outcomes will be subsequently distributed or shared throughout the consortium.
The RDCRN Program has also identified specific areas of interest in accordance with its aim to advance the diagnosis, management, and treatment of rare diseases with a focus on clinical trial readiness. The RDCRN priority research areas that would be appropriate for requests for supplemental funding include, but are not limited to, the topics listed here:
Administrative supplement requests for support of clinical trials will not be accepted and/or considered in response to this funding opportunity announcement.
Applications should demonstrate how the supplement can be completed within the project period. As applicable, the proposed research effort should be supported by a strong rationale and should contribute to advancing translational sciences.
Applicants are strongly encouraged to discuss these potential requests with their Program Official listed in the Notice of Grant Award of the parent grant.
Award Project Period
Administrative supplements are limited to 12 months.
Budget and Available Funds
Supplement budget requests may not exceed $150,000 per year direct costs and must reflect actual needs of the proposed project. There is no guarantee that funds are available from NCATS or for any specific grant.
Application and Submission Information
Eligible Individuals (Program Director/Principal Investigator)
Applicants must hold an active RDCRN award: only parent RDCRN cooperative agreement awards funded through the following FOA (and any reissues of this announcement) are eligible to request supplemental funding under this NOSI:
For supplements to parent awards that include multiple PDs/PIs, the supplement may be requested by any or all of the PDs/PIs (in accordance with the existing leadership plan) and must be submitted by the awardee institution of the parent award.
Submitting an Application
Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.
All instructions in the SF424 (R&R) Application Guide and PA-18-591 must be followed, with the following additions:
Please direct all inquiries to:
Tiina K. Urv, Ph.D.
National Center for Advancing Translational Sciences (NCATS)